Data Monetization Index for Life Sciences

January 11, 2022

Summary

The Data Monetization Index (DMI) for Life Sciences varies by industry and company:

  • Pharmaceutical companies like Merck and Johnson & Johnson have DMIs in the 6%-7% range
  • Smith & Nephew has a DMI of 30.1%, the only pure-play medical device company in our analysis although we did also factor in Johnson & Johnson’s Medical Devices division
  • DNA testing companies firms 23AndMe and Ancestry.com had DMIs in the range of 15%-23%

A higher DMI is generally preferable across companies and industries. By way of reference, internet companies have a higher DMI because most of their enterprise value is derived from data. For example, Google’s DMI is 93 percent as we will discuss in a separate blog.

Definitions

  • Data Monetization Index (DMI) = Data Valuation / Enterprise Value
  • The Data Valuation for Pharmaceuticals and Medical Devices only included Clinical Trials
  • The Data Valuation for DNA testing companies only covered genomic data
  • Enterprise Value =  Equity Value + Long Term Debt – Cash, a key metric used in the investment community

Methodology

Clinical trial data is based on publicly-available datasets from the National Institutes of Health (NIH), SEC filings on product revenues and gross margins, as well as industry estimates of success rates by clinical trial stage. Genomic data valuation is based on comparable transactions in the industry.

Our analysis was conducted in October 2021. 

Other news

We use cookies to ensure we give you the best experience on our website. If you continue to use this site, we will assume you consent to our privacy policy.

This website uses cookies. By continuing to use this site, you accept our use of cookies as described in our Privacy Policy